Insys Therapeutics
-
Former opioid company executives convicted in federal court
The conviction of John Kapoor and others from Insys Therapeutics represents the first successful prosecution of pharmaceutical executives for crimes related to the opioid crisis, US District Attorney Andrew Lelling said.
-
In last Senate testimony, FDA’s Gottlieb highlights agency’s opioid epidemic efforts
The outgoing commissioner requested $55 million to aid the agency’s fight against the opioid epidemic.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Former Insys execs in alleged opioid conspiracy start criminal trial in Boston
The trial – of Insys founder John Kapoor and four other defendants – had been scheduled to start Monday morning. Two other executives pleaded guilty in November and earlier this month.
-
Might opioid addiction be a symptom of our broken primary care system?
Investigative journalism lives in some unlikely places, such as on HBO’s “Last Week Tonight with John Oliver.” This week, host John Oliver — you know, a comedian by trade — took a deep look at the opioid epidemic in America.
-
Insys Therapeutics to swallow NeoPharm in $135M reverse merger
Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology, will swallow Chicago-area biopharmaceutical developer NeoPharm Inc. (OTC:NEOL.PK) through a reverse merger worth an initial $135 million in stock.